19 June 2013
Keywords: sembiosys, gets, 5m, mannkind, plant-based, insulin, canada
Article | 12 January 2009
Canada's SemBioSys Genetics says that US firm MannKind Corp has purchased an option to license rights to its proprietary plant-produced
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 January 2009
18 June 2013
© 2013 thepharmaletter.com